Chilean health authority approves hundreds of bioequivalent drugs
A total of 573 bioequivalent drugs are now part of the national pharmacological plan, thanks to a continuous process that the ISP has implemented allowing the prompt assessment of bioequivalence.
This process has allowed 573 products that correspond to 108 “active ingredients” available for patients since 2009 (when the first equivalent drug was approved). Thus, the average certification from March 2014 to date has reached 22 monthly products.
The development of bioequivalence, included in the Drug Act, stipulates that the recipe must contain the name of the drug recommended by the specialist with the addition of the generic drug name, which is the International Nonproprietary Name (INN). This enables the individual to request a product be exchanged for another bioequivalent that has demonstrated effectiveness in terms of innovative product and has the same results.
The local health authority continually monitors these products in pharmacies so that the user has an option to exchange and access effective treatment and quality in the drugs.
The purpose of bioequivalence, backed by respective studies, is to demonstrate that two drugs containing the same active ingredient at the same dose, are equivalent for patients in terms of quality, efficacy and safety.